^
No biomarker
Uterine Corpus Leiomyosarcoma
pazopanib
Sensitive: A2 - Guideline
ER positive
Uterine Corpus Leiomyosarcoma
Aromatase inhibitor
Sensitive: A2 - Guideline
PGR positive
Uterine Corpus Leiomyosarcoma
Aromatase inhibitor
Sensitive: A2 - Guideline
PGR positive
Uterine Corpus Leiomyosarcoma
medroxyprogesterone
Sensitive: A2 - Guideline
ER positive
Uterine Corpus Leiomyosarcoma
medroxyprogesterone
Sensitive: A2 - Guideline
PGR positive
Uterine Corpus Leiomyosarcoma
megestrol
Sensitive: A2 - Guideline
ER positive
Uterine Corpus Leiomyosarcoma
megestrol
Sensitive: A2 - Guideline
AKT1 E17K
Uterine Corpus Leiomyosarcoma
AZD5363
Sensitive: C3 – Early Trials
CD70 expression
Uterine Corpus Leiomyosarcoma
ARX305
Sensitive: C3 – Early Trials
ER positive + PGR positive
Uterine Corpus Leiomyosarcoma
anastrozole
Sensitive: C3 – Early Trials
PGR positive
Uterine Corpus Leiomyosarcoma
anastrozole
Sensitive: C3 – Early Trials
ER positive
Uterine Corpus Leiomyosarcoma
anastrozole
Sensitive: C3 – Early Trials
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
lorlatinib
Sensitive: C4 – Case Studies
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
alectinib
Sensitive: C4 – Case Studies
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
crizotinib
Resistant: C4 – Case Studies
FN1-ALK fusion
Uterine Corpus Leiomyosarcoma
pazopanib
Resistant: C4 – Case Studies